Multiple sclerosis (MS): microglia cells damage the myelin sheath of neuron...
Multiple sclerosis (MS): microglia cells damage the myelin sheath of neuron axons

Image source: Adobe Stock/Juan Gärtner 

News • MS biomarker

Blood marker gives new insights into multiple sclerosis

Nerve damage in multiple sclerosis (MS) can be detected via the concentration of neurofilament light chain in the blood. According to researchers from the University of Basel and University Hospital Basel, this neuron-specific protein provides valuable information on future disease course and the effectiveness of therapies.

MS is a chronic inflammatory disease of the central nervous system that leads to transient or permanent functional impairment of functions of the nervous system and eventually increasing disability. However, the disease can worsen very differently from person to person, making it difficult to detect disease activity early and accurately and hence tailor treatment to individual needs. Researchers led by Professor Jens Kuhle have now described the importance of the protein neurofilament light chain (NfL), which occurs exclusively in nerve cells, as a valuable and specific marker for nerve damage in MS. They have reported their findings in the journal Lancet Neurology.

Photo
Schematics of a neuron damaged by MS

Image source: University of Basel, University Hospital Basel

For their study, the researchers determined NfL concentrations in more than 20,000 blood samples from over 10,000 patients with MS and healthy control persons (see box). They were able to assess the effects of aging and body weight on normal concentrations measured in healthy control persons, and thereby to determine more precisely determine the threshold to pathologically elevated levels in patients. They used the data to create a large, international reference database that enabled them to identify increased values of NfL in individual blood samples of patients with MS in a meaningful way, indicative of ongoing disease activity. This method also allowed the team to better compare the efficacy of different MS therapies. 

In two large independent groups of people with MS, a strong correlation was found between elevated levels of NfL in the blood and current disease activity in the central nervous system. Strikingly, the researchers, using this precise method, also detected elevated NfL levels in a group of MS sufferers in whom the disease did not appear to be active according to conventional and standard of care criteria. “Even if the condition of those affected appears to be stable with the clinical and imaging methods available today, the damage to the nervous system appears to progress insidiously and initially unnoticed in some cases,” explains Dr. Pascal Benkert, who shares first authorship of the study with PhD student Stephanie Meier. 

In addition, the Clinical Neuroimmunology Research Group, which is based in the Departments of Clinical Research and Biomedicine, shows that this blood marker also allows certain predictions to be made: patients with high NfL concentrations in the blood thus have an increased risk of future MS disease activity. They are more likely to experience inflammatory episodes or a deterioration in their health. 

The results of the study show that this blood marker allows for more accurate assessments of disease activity compared with the methods used previously. “The results offer hope that it will be possible to more precisely chose and tailor therapy to individual disease courses,” says study leader Kuhle. “This is an important step towards individualized MS therapy that is tailored to the patient.” 


Source: University of Basel

18.02.2022

Read all latest stories

Related articles

Photo

News • Beyond polygenic risk scores

Adding blood biomarkers to genomics to better predict common disease risk

New research suggests that combining blood biomarkers with genomic information more accurately, cost-effectively predicts the risk of developing diseases.

Photo

News • Parkinson disease detection

Low-cost sensor detects early-stage Parkinson's disease in biological samples

Researchers at the University of Campinas and the Federal University of São Carlos in Brazil have developed an electrochemical sensor that detects Parkinson's disease at different stages.

Photo

News • Promising biomarker found

Who will develop long Covid? It's in the blood

New research has found molecular signature differences in the blood of patients who fully recover from Covid-19 and those who develop long Covid.

Related products

Beckman Coulter · Early Sepsis Indicator

Blood Cell Counter

Beckman Coulter · Early Sepsis Indicator

Beckman Coulter Diagnostics
Alphenix Biplane High Definition Detector

Bi-Plane

Canon · Alphenix Biplane High Definition Detector

Canon Medical Systems Europe B.V.
Alsachim · Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

Alsachim · Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Alsachim · Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim · Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Beckman Coulter · Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter · Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Beckman Coulter · DxH 500 Series

Blood Cell Counter

· Beckman Coulter · DxH 500 Series

Beckman Coulter Diagnostics
Subscribe to Newsletter